US FDA Outlines Streamlined Development Path For Targeted Therapies
But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.
You may also be interested in...
US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications
Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.
Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record
New oncologics bring CDER’s novel agent approvals count to 53 for the year.
Antibiotic Development Question: Should A Phage Library Equal One Application?
FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.